A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The present invention provides a method for providing information for diagnosis of metastasis of radiotherapy-treated lung cancer, the method comprising the steps of: (a) measuring an expression level of receptor-interacting protein kinase 1 (RIP1) in a sample from a lung cancer patient who has undergone radiotherapy; (b) measuring an expression level of RIP1 in a normal control sample; and (c) comparing the expression levels of step (a) and step (b).

The present disclosure provides methods of risk stratification for the development of lung cancer and/or lung cancer recurrence, methods of treatment of a human having lung cancer with therapeutic agents for preventing estrogen metabolite production, and methods of treating a human having a high risk of developing lung cancer with therapeutic agents for preventing estrogen metabolite production.

Described herein are methods for screening for a disease state. The method may include obtaining multiple data sets, and identifying the disease state based on a combination of the data sets. The data sets may include biomolecule measurements obtained by multiple methods, such as through the use of particles and reference biomolecules.

Methods for measuring subpopulations of target molecules (e.g., polypeptides and/or cell-free ribonucleic acid) are provided. In some embodiments, methods of generating a sequencing library from a plurality of RNA molecules in a test sample obtained from a subject are provided, as well as methods for analyzing the sequencing library to detect, e.g., the presence or absence of a disease.

A method for predicting whether an early stage (IA, IB) non-small-cell lung cancer (NSCLC) patient is at a high risk of recurrence of the cancer following surgery involves subjecting a blood-based sample from the patient (obtained prior to, at, or after the surgery) to mass spectrometry and classification with a computer implementing a classifier. If the patients blood sample is classified as “high risk”, highest risk“or the equivalent, the patient can be guided to more aggressive treatment post-surgery. The classifier, or combination of classifiers, can be arranged in a hierarchical manner to make intermediate classifications, such as intermediate/high or intermediate/low, as well as low risk” or “lowest risk” classifications. Such additional classifications may guide clinical decisions as well.

From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.

The present invention relates to a composition for diagnosing lung cancer including a preparation capable of measuring expression levels of lung cancer-specific biomarkers SAA, OPN, and CEA at the same time, a kit for diagnosing lung cancer including the same, and a method of diagnosing lung cancer using the composition. The composition for diagnosing lung cancer has effects such as enhanced sensitivity and specificity as compared to conventional biomarkers, thereby exhibiting high diagnostic efficiency.

A system and method for the detection of saliva biomarkers in bodily fluids is described. In particular, the system is suitable for detecting biomarkers of lung cancer in a subject. The system includes an electrochemical sensor chip having at least one well, wherein the at least one well contains a working electrode coated with a conducting polymer functionalized with at least one capture probe, and at least one labeled detector probe. When the at least one labeled detector probe is mixed with a sample of the subject containing a biomarker of lung cancer and added to the at least one well, an electric current is applied to the sample, such that when at least some of the biomarker binds to the capture probe, a measurable change in electric current in the sample is created that is indicative of lung cancer.